Received: 13 January 2018
Accepted: 28 December 2018
First Online: 17 January 2019
Ethics approval and consent to participate
: The study received approval by the “Fondazione Policlinico Gemelli” Ethics Committee (protocol number: 10978/15), and every patient signed an informed consent before data collection.
: Not applicable.
: AB reports non-financial support from Bristol Myers Squibb, personal fees from Gilead Sciences, non-financial support from ViiV Healthcare, outside the submitted work. RG reports travel grants from Gilead and from Janssen-Cilag, outside the submitted work. FM reports non-financial support from Angelini, and a contract research from Novartis Vaccine and Diagnostics S.r.l., outside the submitted work. EV reports personal fees from Merck Sharp and Dohme. ADL reports grants and personal fees from Gilead, personal fees from Bristol-Myers Squibb, grants and personal fees from ViiV, personal fees from Abbvie, personal fees from Janssen, grants and personal fees from Merck Sharp and Dohme, outside the submitted work. ADL also declares to be member of the editorial board (Associate Editor) of BMC Infectious Diseases. SDG reports personal fees from Bristol-Myers Squibb, personal fees from Gilead Sciences, personal fees from Boehringer Ingelheim, personal fees from Janssen-Cilag, personal fees from GlaxoSmithKline, outside the submitted work. All other authors have nothing to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.